FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2151787066> ?p ?o ?g. }

• W2151787066 endingPage "698" @default.
• W2151787066 startingPage "693" @default.
• W2151787066 abstract "OBJECTIVES We sought to determine whether the observed benefits of enoxaparin were maintained beyond the early phase; a one-year follow-up survey was undertaken for patients enrolled in the Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q wave Coronary Events (ESSENCE) study. BACKGROUND We have previously reported a significant benefit of low molecular weight as compared with unfractionated heparin (UFH) in the 14- and 30-day incidence of a composite end point of death, myocardial infarction (MI) or recurrent angina in patients with unstable angina or non–Q wave MI. METHODS The study recruited 3,171 patients with recent-onset rest angina and underlying ischemic heart disease. All patients received oral aspirin daily and were randomized to receive enoxaparin subcutaneously every 12 h or UFH (intravenous bolus followed by continuous infusion) in a double-blind, double-dummy fashion for a median of 2.6 days. RESULTS The incidence of the composite triple end point at one year was lower among patients receiving enoxaparin as compared with those receiving UFH (32.0% vs. 35.7%, p = 0.022), with a trend toward a lower incidence of the secondary composite end point of death or MI (11.5% vs. 13.5%, p = 0.082). At one year, the need for diagnostic catheterization and coronary revascularization was lower in the enoxaparin group (55.8% vs. 59.4%, p = 0.036 and 35.9% vs. 41.2%, p = 0.002, respectively). CONCLUSIONS In patients with unstable angina or non–Q wave MI, enoxaparin therapy significantly reduced the rates of recurrent ischemic events and invasive diagnostic and therapeutic procedures in the short term with sustained benefit at one year." @default.
• W2151787066 created "2016-06-24" @default.
• W2151787066 creator A5002603121 @default.
• W2151787066 creator A5010333539 @default.
• W2151787066 creator A5020282147 @default.
• W2151787066 creator A5026102047 @default.
• W2151787066 creator A5039466154 @default.
• W2151787066 creator A5047187243 @default.
• W2151787066 creator A5052994249 @default.
• W2151787066 creator A5055694232 @default.
• W2151787066 creator A5060829829 @default.
• W2151787066 creator A5064518760 @default.
• W2151787066 creator A5077297087 @default.
• W2151787066 creator A5080382536 @default.
• W2151787066 date "2000-09-01" @default.
• W2151787066 modified "2023-10-18" @default.
• W2151787066 title "Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease∗∗∗∗A list of participating ESSENCE Study Group investigators may be found in N Engl J Med 1997;337:447–52." @default.
• W2151787066 cites W1581187193 @default.
• W2151787066 cites W1970472124 @default.
• W2151787066 cites W1984761420 @default.
• W2151787066 cites W2021137067 @default.
• W2151787066 cites W2021206861 @default.
• W2151787066 cites W2032105970 @default.
• W2151787066 cites W2057492075 @default.
• W2151787066 cites W2075196907 @default.
• W2151787066 cites W2091795351 @default.
• W2151787066 cites W2145710740 @default.
• W2151787066 cites W2149599987 @default.
• W2151787066 cites W2185274417 @default.
• W2151787066 cites W2316460201 @default.
• W2151787066 cites W2969335355 @default.
• W2151787066 cites W3194355700 @default.
• W2151787066 cites W367384902 @default.
• W2151787066 cites W4361865076 @default.
• W2151787066 cites W1512144932 @default.
• W2151787066 doi "https://doi.org/10.1016/s0735-1097(00)00808-1" @default.
• W2151787066 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10987586" @default.
• W2151787066 hasPublicationYear "2000" @default.
• W2151787066 type Work @default.
• W2151787066 sameAs 2151787066 @default.
• W2151787066 citedByCount "156" @default.
• W2151787066 countsByYear W21517870662012 @default.
• W2151787066 countsByYear W21517870662013 @default.
• W2151787066 countsByYear W21517870662014 @default.
• W2151787066 countsByYear W21517870662015 @default.
• W2151787066 countsByYear W21517870662016 @default.
• W2151787066 countsByYear W21517870662017 @default.
• W2151787066 countsByYear W21517870662018 @default.
• W2151787066 countsByYear W21517870662019 @default.
• W2151787066 countsByYear W21517870662023 @default.
• W2151787066 crossrefType "journal-article" @default.
• W2151787066 hasAuthorship W2151787066A5002603121 @default.
• W2151787066 hasAuthorship W2151787066A5010333539 @default.
• W2151787066 hasAuthorship W2151787066A5020282147 @default.
• W2151787066 hasAuthorship W2151787066A5026102047 @default.
• W2151787066 hasAuthorship W2151787066A5039466154 @default.
• W2151787066 hasAuthorship W2151787066A5047187243 @default.
• W2151787066 hasAuthorship W2151787066A5052994249 @default.
• W2151787066 hasAuthorship W2151787066A5055694232 @default.
• W2151787066 hasAuthorship W2151787066A5060829829 @default.
• W2151787066 hasAuthorship W2151787066A5064518760 @default.
• W2151787066 hasAuthorship W2151787066A5077297087 @default.
• W2151787066 hasAuthorship W2151787066A5080382536 @default.
• W2151787066 hasConcept C120665830 @default.
• W2151787066 hasConcept C121332964 @default.
• W2151787066 hasConcept C126322002 @default.
• W2151787066 hasConcept C141071460 @default.
• W2151787066 hasConcept C164705383 @default.
• W2151787066 hasConcept C168563851 @default.
• W2151787066 hasConcept C203092338 @default.
• W2151787066 hasConcept C2776884760 @default.
• W2151787066 hasConcept C2777557582 @default.
• W2151787066 hasConcept C2777628954 @default.
• W2151787066 hasConcept C2777785093 @default.
• W2151787066 hasConcept C2778213512 @default.
• W2151787066 hasConcept C2778425758 @default.
• W2151787066 hasConcept C2778825682 @default.
• W2151787066 hasConcept C2779464278 @default.
• W2151787066 hasConcept C500558357 @default.
• W2151787066 hasConcept C61511704 @default.
• W2151787066 hasConcept C71924100 @default.
• W2151787066 hasConceptScore W2151787066C120665830 @default.
• W2151787066 hasConceptScore W2151787066C121332964 @default.
• W2151787066 hasConceptScore W2151787066C126322002 @default.
• W2151787066 hasConceptScore W2151787066C141071460 @default.
• W2151787066 hasConceptScore W2151787066C164705383 @default.
• W2151787066 hasConceptScore W2151787066C168563851 @default.
• W2151787066 hasConceptScore W2151787066C203092338 @default.
• W2151787066 hasConceptScore W2151787066C2776884760 @default.
• W2151787066 hasConceptScore W2151787066C2777557582 @default.
• W2151787066 hasConceptScore W2151787066C2777628954 @default.
• W2151787066 hasConceptScore W2151787066C2777785093 @default.
• W2151787066 hasConceptScore W2151787066C2778213512 @default.
• W2151787066 hasConceptScore W2151787066C2778425758 @default.
• W2151787066 hasConceptScore W2151787066C2778825682 @default.
• W2151787066 hasConceptScore W2151787066C2779464278 @default.
• W2151787066 hasConceptScore W2151787066C500558357 @default.
• W2151787066 hasConceptScore W2151787066C61511704 @default.

• next